Compugen (NASDAQ:CGEN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Monday, May 14th. The firm presently has a $3.75 price objective on the biotechnology company’s stock. Zacks Investment Research‘s target price points to a potential upside of 17.19% from the company’s current price.
According to Zacks, “Compugen Ltd. is a pioneer in the fields of computational genomics and proteomics. The company combines the disciplines of mathematics and computer science with molecular biology to improve the understanding of genomics and proteomics, the study of genes and proteins. Compugen’s expertise in these areas is used to develop core technologies and platforms that are the basis for its products and services. These products and services are designed to enable life scientists to significantly enhance their research efforts in drug discovery. “
A number of other equities research analysts have also issued reports on CGEN. ValuEngine lowered Compugen from a “hold” rating to a “sell” rating in a research report on Friday, May 11th. Oppenheimer assumed coverage on Compugen in a research report on Thursday, March 29th. They set an “outperform” rating and a $9.00 target price on the stock. Finally, CIBC assumed coverage on Compugen in a research report on Thursday, March 29th. They set an “outperform” rating on the stock.
Compugen (NASDAQ:CGEN) last issued its earnings results on Wednesday, February 21st. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter. equities analysts predict that Compugen will post -0.44 earnings per share for the current fiscal year.
Large investors have recently added to or reduced their stakes in the stock. Paloma Partners Management Co purchased a new position in Compugen during the 4th quarter worth approximately $105,000. Virtu Financial LLC purchased a new position in Compugen during the 4th quarter worth approximately $162,000. Jane Street Group LLC purchased a new position in Compugen during the 4th quarter worth approximately $192,000. Benjamin F. Edwards & Company Inc. grew its stake in shares of Compugen by 35.4% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 85,300 shares of the biotechnology company’s stock valued at $213,000 after purchasing an additional 22,305 shares during the last quarter. Finally, A.R.T. Advisors LLC purchased a new position in shares of Compugen in the 1st quarter valued at approximately $265,000. Hedge funds and other institutional investors own 21.23% of the company’s stock.
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's pipeline primarily includes early and preclinical stage immuno-oncology programs based on novel drug targets, such as immune checkpoint and myeloid protein target candidates to harness the immune system to provide treatment solutions in the areas of unmet medical needs in various cancer types and patient populations.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.